AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article

Nanomedicine-mediated ubiquitination inhibition boosts antitumor immune response via activation of dendritic cells

Jilong Wang1,3Mengwen Huang1Senbiao Chen2Yingli Luo2,6Song Shen1,7Xiaojiao Du2,3,4,5( )
School of Biomedical Sciences and Engineering South China University of Technology Guangzhou International Campus Guangzhou 510006 China
Institutes for Life Sciences School of Medicine South China University of Technology Guangzhou 510006 China
National Engineering Research Center for Tissue Restoration and Reconstruction South China University of Technology Guangzhou 510006 China
Key Laboratory of Biomedical Engineering of Guangdong Province South China University of Technology Guangzhou 510006 China
Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory) Guangzhou 510005 China
Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education South China University of Technology Guangzhou 510006 China
Innovation Center for Tissue Restoration and Reconstruction South China University of Technology Guangzhou 510006 China
Show Author Information

Abstract

Tumor immunotherapy as a promising method for tumor treatment received tremendous attention. However, the problem of low clinical response rate still needs to be solved, especially in the poorly immunogenic tumors. The enhancement of tumor antigens presentation can effectively activate dendritic cells (DCs) and improve the tumor immunotherapy. In this work, TAK-243 as an inhibitor of the ubiquitin activating enzyme (UAE), was fabricated into cationic lipid-assisted nanoparticle (CLANTAK-243). The obtained CLANTAK-243 could act as an effective tumor immunotherapy enhancer to promote the maturation of DCs as well as antigen presentation, which obviously stimulated the T cells activation and proliferation. Such CLANTAK-243 injected intravenously could well trigger immune response to tumor cells in vivo. Importantly, mice treated with CLANTAK-243 could obtain a long immune memory effect to protect themselves from re-challenged tumor cells. Therefore, this work presented an effective immunotherapy strategy for poorly immunogenic tumor.

Graphical Abstract

Electronic Supplementary Material

Download File(s)
12274_2021_3312_MOESM1_ESM.pdf (2.2 MB)

References

【1】
【1】
 
 
Nano Research
Pages 3900-3906

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Wang J, Huang M, Chen S, et al. Nanomedicine-mediated ubiquitination inhibition boosts antitumor immune response via activation of dendritic cells. Nano Research, 2021, 14(11): 3900-3906. https://doi.org/10.1007/s12274-021-3312-4
Topics:

1557

Views

14

Crossref

15

Web of Science

14

Scopus

2

CSCD

Received: 25 August 2020
Revised: 30 December 2020
Accepted: 02 January 2021
Published: 25 January 2021
© Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2021